gsk1120212
Metastatic Uveal Melanoma
Alliance for Clinical Trials in OncologyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 81/ 100
Competitive context
23 Active assets in the Metastatic Uveal Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Beijing Biotech | Phase 2/3 | BB |
Evomela Vastra Gotaland Region | Phase 3 | BB |
DACARBAZINE IDEAYA Biosciences | Phase 3 | BB |
Nivolumab Inge Marie Svane | Phase 3 | BB |
Crizotinib IDEAYA Biosciences | Phase 2/3 | BB |
View all 35 →
Same molecule, other indications
gsk1120212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →